10-Q: Genprex Reports First Quarter 2024 Results, Provides Clinical Trial Updates

Genprex, Inc. reported a net loss of $5.97 million for the first quarter of 2024, while advancing its clinical programs for cancer and diabetes.

Summary

• Genprex, Inc. reported a net loss of $5.97 million for the first quarter of 2024, compared to a net loss of $9.20 million for the same period in 2023.
• The company's research and development expenses decreased to $3.27 million from $5.31 million year-over-year.
• General and administrative expenses also decreased to $2.72 million from $3.95 million year-over-year.
• The company completed a 1-for-40 reverse stock split on February 2, 2024.
• Genprex raised approximately $5.8 million in net proceeds from a registered direct offering in March 2024.
• As of March 31, 2024, Genprex had $8.22 million in cash and cash equivalents.
• The company expects its current cash to fund operations into the third quarter of 2024.
• Genprex is actively enrolling patients in Phase 1/2 clinical trials for its lead oncology drug candidate, REQORSA, in combination with other cancer drugs.
• The company is also advancing its diabetes gene therapy program, with plans to seek regulatory guidance for IND-enabling studies in 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and cost management, the company's financial position is precarious, with a limited cash runway and material weaknesses in internal controls. The going concern warning is a significant negative factor.

Positives

• The company's net loss decreased significantly year-over-year, indicating improved cost management.
• Research and development expenses decreased, suggesting more efficient use of resources.
• The company successfully raised additional capital through a registered direct offering.
• Genprex is actively enrolling patients in multiple clinical trials, demonstrating progress in its drug development programs.
• The company has received Fast Track Designation from the FDA for multiple treatment combinations, which could expedite the regulatory review process.
• The company has received Orphan Drug Designation for REQORSA for the treatment of SCLC.
• The company is advancing its diabetes program with plans to seek regulatory guidance for IND-enabling studies in 2024.

Negatives

• The company continues to operate at a loss and has an accumulated deficit of $139.66 million.
• The company's cash reserves are expected to fund operations only into the third quarter of 2024, indicating a need for additional financing.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company has a history of losses and no current source of revenue.
• The company is dependent on third-party suppliers and manufacturers.
• The company has a going concern warning.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and the need for additional financing.
• There are material weaknesses in the company's internal controls over financial reporting.
• The company is dependent on the success of its clinical trials, which are subject to various risks and uncertainties.
• The company may face delays in regulatory review and approval of its product candidates.
• The company is dependent on third-party suppliers and manufacturers, which could lead to supply chain disruptions.
• The company may not be able to raise additional capital when needed on favorable terms, or at all.
• The company faces competition from larger and better-financed biotechnology and pharmaceutical companies.
• The company is subject to risks associated with intellectual property litigation.

Future Outlook

Genprex expects its current cash and cash equivalents to fund operations into the third quarter of 2024. The company plans to continue advancing its clinical trials and seek regulatory guidance for its diabetes program. Genprex anticipates needing to raise additional capital to fund future operations.

Management Comments

• Management is actively engaged in remediation efforts to address the material weaknesses identified in the managements evaluation of internal controls and procedures.
• Management believes that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

Industry Context

Genprex is operating in the competitive biotechnology and pharmaceutical industry, focusing on gene therapy for cancer and diabetes. The company's approach of combining its therapies with existing approved drugs is a common strategy in the industry to improve treatment outcomes. The company's focus on unmet medical needs aligns with broader industry trends in developing innovative therapies for challenging diseases.

Comparison to Industry Standards

• Genprex's cash burn rate is typical for a clinical-stage biotech company, but the company's cash runway is shorter than some of its peers.
• The company's reliance on external funding is common in the biotech industry, but the company's ability to raise additional capital is a key risk.
• The company's clinical trial progress is in line with industry standards, but the company's success will depend on the efficacy and safety of its therapies.
• The company's focus on gene therapy is a growing area in the biotech industry, but the company faces competition from other companies developing similar therapies.
• The company's internal control weaknesses are a concern, as they are not in line with industry best practices for public companies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently involved in any material legal proceedings.

Related Party Transactions

• The company has an Assignment and Collaboration Agreement with Introgen Research Institute (IRI), a company formed by the company's former President, Chief Executive Officer and Chairman of the Board, Rodney Varner. There were no amounts incurred or due under this agreement at March 31, 2024 and December 31, 2023.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises additional capital through equity offerings.
• Employees may be affected by the company's financial challenges and potential restructuring.
• Customers (potential patients) may benefit from the company's drug development programs if they are successful.
• Suppliers and creditors may be affected by the company's financial condition and ability to pay its obligations.

Next Steps

• The company will continue to enroll patients in its Acclaim-1, Acclaim-2, and Acclaim-3 clinical trials.
• The company expects to complete enrollment of 19 patients in each cohort of the Acclaim-1 Phase 2a expansion study by the end of 2024.
• The company expects to complete the Phase 1 dose escalation portion of the Acclaim-2 study in the second half of 2024.
• The company expects to complete the Phase 1 dose escalation portion of the Acclaim-3 study during the second half of 2024 and start the Phase 2 expansion portion in the second half of 2024.
• The company will continue with nonclinical studies for its diabetes program and plans to request regulatory guidance in 2024 for IND-enabling studies.
• The company will continue to implement remediation plans to address the material weaknesses in its internal controls over financial reporting.
• The company will need to raise additional capital to fund its future operations.

Key Dates

Keywords

Genprex, REQORSA, gene therapy, clinical trials, lung cancer, diabetes, Oncoprex Delivery System, TUSC2, financial results, registered direct offering, reverse stock split, Fast Track Designation, Orphan Drug Designation